CHARM: COVID-19 Health Action Response for Marines – association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test

Martha Sedegah^{1,@}, Chad Porter², Michael R. Hollingdale^{1,3,@}, Harini Ganeshan^{1,3}, Jun Huang^{1,3}, Carl W. Goforth², Maria Belmonte^{1,3}, Arnel Belmonte^{1,4}, Dawn L. Weir², Rhonda A. Lizewski⁵, Stephen E. Lizewski⁵, Stuart C. Sealfon⁶, Vihasi Jani^{2,3}, Ying Cheng^{2,7}, Sandra Inoue^{1,3}, Rachael Velasco¹, Eileen Villasante¹, Peifang Sun², and Andrew Letizia^{2,@}.

Affiliations

¹Naval Medical Research Center, Malaria Department, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, USA

²Naval Medical Research Center, Virology Department, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, USA

³Henry M. Jackson Foundation, 6720A Rockledge Dr., Bethesda, MD 20817, USA

⁴GDIT Maryland 20817, USA

⁵U.S. Naval Medical Research Unit SIX, Lima, Perú

⁶Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl., New York, NY 10029, USA

⁷Leidos, 1750 Presidents Street, Reston, VA 20190, USA

[@] Corresponding Authors

ABSTRACT

SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- and Class II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) and membrane (M) proteins and others. This prospective COVID-19 Health Action Response for Marines (CHARM) study enabled assessment of T cell responses in symptomatic and asymptomatic SARS-CoV-2 infected participants.

At enrollment all participants were negative by qPCR; follow-up occurred biweekly and then bimonthly for the next 6 weeks. Study participants who tested positive by qPCR SARS-CoV-2 test were asked to enroll in an immune response sub-study. FluoroSpot interferon-gamma (IFN- γ) and IL2 responses following qPCR-confirmed infection at enrollment (day 0), day 7 and 14 and more than 28 days later were measured using pools of 17mer peptides covering S, N, and M proteins, or CD4+CD8 peptide pools containing predicted epitopes from multiple SARS-CoV-2 antigens.

Among 124 asymptomatic and 105 symptomatic participants, SARS-CoV-2 infection generated IFN- γ responses to the S, N and M proteins that persisted longer in asymptomatic cases. IFN- γ responses were significantly ($p=0.001$) more frequent to the N pool (51.4%) than the M pool (18.9%) among asymptomatic subjects; however, the difference was not statistically significant ($p=0.06$) for symptomatic subjects (N pool: 44.4%; M pool: 25.9%). In asymptomatic participants IFN- γ responders to the CD4+CD8 pool responded more frequently to the S pool (55.6%) and N pool (57.1%), than the M pool (7.1%), but symptomatic participants, IFN- γ responses were more frequent to the S pool (75.0%) than N pool (33.3%) and M pool (33.3%). The frequencies of IFN- γ responses to the S and N+M pools peaked 7 days after the positive

qPCR test among asymptomatic (S pool: 22.2%; N+M pool: 28.7%) and symptomatic (S pool: 15.3%; N+M pool 21.9%) participants and dropped by >28 days. Magnitudes of post-infection IFN- γ and IL2 responses to the N+M pool were significantly correlated with IFN- γ and IL2 responses to the N and M pools.

These data further support the central role of Th₁-biased cell mediated immunity IFN- γ and IL2 responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-based COVID-19 vaccines that include the N and S proteins.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1], is responsible for more than 220 million confirmed cases, and more than 4.5 million deaths as of September 5, 2021 (COVID-19 report of the World Health Organization). Clinically, SARS-CoV-2 infection ranges from asymptomatic infection to severe illness including acute respiratory distress syndrome (ARDS), and death.

COVID-19 vaccines that induce neutralizing antibodies particularly to the spike (S) protein have been approved for emergency use in the USA, and one, the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) has received U.S. Food and Drug Administration (FDA) approval. However, the efficacy of these vaccines against evolving strains with mutations in the S-protein remains to be fully elucidated [2]. While efforts are ongoing to develop vaccines that incorporate known variant sequences in the next generation S-based COVID-19 vaccines, future vaccines may also need to incorporate other antigenic targets of protective T cell immunity. Other future vaccines involving attenuated whole virus may also be considered. The crucial role of T cell immunity in COVID-19, and persistence of SARS-CoV-2-specific T cell immunity, has critical consequences for vaccine development [3-6]. Antigen-specific T cell responses could support the inclusion of additional antigenic vaccine targets in next generation COVID-19 vaccines. Such vaccines may enhance, broaden, and prolong protective cellular and humoral immunity against COVID-19 by targeting immunodominant regions of multiple antigenic targets and provide T cell-mediated immunity against variants that may escape antibody mediated immunity targeting just the Spike protein.

Since T cells play a vital role in protective immunity against SARS-CoV-2 [7], robust induction of T cell responses by vaccines will be crucial. It is important to understand the range of T cell responses to T cell epitopes of SARS-CoV-2, and *in silico* methods have been used to predict epitopes, often using machine learning [8]. These methods either exploit genetic similarities between SARS-CoV-2 and SARS-CoV particularly for structural proteins S, N, M and E-proteins [9, 10] or peptide-HLA binding prediction methods [8] using artificial neural networks including NetMHCpan derived methods [11-14]. However, many of the predicted epitopes have proven to be non-immunogenic and the accuracy of these predictions can be validated by experimental data [15]. Internal viral proteins are usually more conserved than surface proteins and are often the targets of CD8⁺ T cells, emphasizing the relative importance of the N-protein among others [16, 17]. Defining a comprehensive set of epitopes enables the breadth of responses and number of epitopes among infected individuals and may help explain heterologous clinical outcomes [7, 18-20].

This study was designed to comprehensively measure IFN- γ cell responses in the COVID-19 Health Action Response for Marines (CHARM) study, a prospective, longitudinal cohort study of healthy, young adults [21]. This cohort enabled the evaluation of immune responses in symptomatic and asymptomatic SARS-CoV-2 infections, as well as in uninfected participants.

METHODS

Ethics

The CHARM study was conducted at the Marine Corps Recruitment Depot, Parris Island, South Carolina and has been previously described [21]. Institutional Review Board approval was obtained from the Naval Medical Research Center (protocol number NMRC.2020.0006) in compliance with all applicable US federal regulations governing the protection of human participants. All participants provided written informed consent.

Study Participants

As previously reported [21], after completing a 14-day home quarantine, recruits who were 18 years or older were eligible to participate. Only those who had a negative qPCR for SARS-CoV-2, at enrollment were considered for this analysis. A 14-question clinical assessment was administered [22], mid-turbinate nares swab specimens obtained for qPCR to detect SARS-CoV-2, and peripheral blood mononuclear cells (PBMCs) were collected at enrollment [22]. Study participants were followed-up on days 7 and 14, 28, 42, and 56 after enrollment at which time they reported symptoms since the last encounter and had qPCR testing for SARS-CoV-2 repeated.

Study Design

The complete design of this study is shown in Figure 1. Peripheral PBMCs were obtained at enrollment (T0). Additional qPCR testing was performed at days 3/4, 7, 10/11, 14, 28, 42 and 56. Participants with a positive qPCR test were asked to participate in an immune response sub-study. If willing, consented subjects underwent further qPCR tests performed biweekly within

the first 14 days after infection, and then bimonthly at 28, 42 and 56 days. Blood was drawn at each of these time points. Samples were categorized into 3 groups: samples obtained in the first week after the initial qPCR positivity (T7), samples obtained in the second week after qPCR positivity (T14), and >15 days after qPCR positivity (long-term, TLT). All participants completed a questionnaire reporting 14 specific COVID-19 related symptoms and were characterized as asymptomatic (124 participants) for those with no symptoms, and symptomatic (105 participants) for those with any reported COVID-19 symptoms.

Immune samples

PBMCs for measuring cell-mediated immunity (FluoroSpot assay) were collected at the time of enrollment (T0) and then after the participant's first positive qPCR test (T7, T14, TLT), isolated from heparin tubes within 24 hours, and stored in liquid nitrogen until used. Cryopreserved PBMCs were thawed, washed, counted, and used in the FluoroSpot assay to measure cells secreting either interferon-gamma (IFN- γ), Interleukin-2 (IL2), as previously reported [23-25].

Peptide pools

All peptides were obtained from BEI Resources (Manassas, VA). The full-length spike glycoprotein (S), full length nucleocapsid (N) protein, and the membrane (M) protein were each covered by a series of 17-mer or 13-mer (aa) peptides overlapping by 10 amino acids that were combined into antigen-specific peptide pools. The S protein pool contained 181 peptides, the N

protein pool contained 59 peptides, and the M protein pool contained 31 peptides. In addition, all N and M peptides were combined into a single N+M pool. Samples were tested against the S pool and the N+M pool. Based on availability of cells in some participants, we tested individual antigenic pools of N peptide and M peptide pools. The CD4+ and CD8+ T epitopes peptide pool (kindly provided by Dr. Alessandro Sette, La Jolla Institute for Immunology) [9] and their distribution among SARS-CoV-2 proteins is shown in Supplementary Table S1. CD4+ epitopes were synthesized as 241 15-mers and CD8+ epitopes were synthesized as 628 8-13-mers that were combined into one CD4+ and CD8+ peptide pool [9]. Due to limited PBMCs, not all participants were tested with the CD4+CD8 peptide pool.

Interferon-gamma/IL2 FluoroSpot assay

Antigen-specific circulating PBMCs were evaluated using pre-coated FluoroSpot plates and kits purchased from Mabtech (Mabtech AB, Nacka Strand, Sweden) and used according to the manufacturer's instructions. The previously described *ex vivo* ELISpot was modified [26]; briefly, 2-3 x 10⁵ PBMCs suspended in 100 µL complete medium were incubated in the FluoroSpot plates with antigen-specific peptide pool at final concentration of 2 µg/mL suspended in 100 µL complete medium. CTL-CEF-Class I Peptide Pool Plus (Cellular Technology Ltd, Cleveland, OH) consisting of 32 peptides corresponding to defined HLA class I-restricted T cell epitopes from cytomegalovirus, Epstein-Barr virus and influenza virus was used as an internal control for each participant. PHA, a mitogen, was used as a positive control for cell viability. Negative control unstimulated PBMCs received medium only. Cultures were incubated for 40-42 h at 37°C in 5% CO₂. Each PBMC sample was assayed in duplicate and the number of single-

staining antigen-specific IFN γ - and IL2-secreting cells and double-staining IFN γ - and IL2-secreting cells were recognized as spot-forming cells (sfc) and enumerated using an automated FluoroSpot reader (AID iSpot, Autoimmun Diagnostika GmbH, Strasberg, Germany). After subtraction of the mean number of sfc in negative control wells (no antigen), the mean of the net sfc of the test sample was expressed as sfc/10⁶ PBMCs. A positive response to each individual peptide pool was defined as positive when there was a statistically significant difference ($p \leq 0.05$) between the average of the sfc in test and negative control wells (Student's two tailed t -test), plus at least a doubling of sfc in test compared to control wells, plus a difference of at least 10 sfc between test and control wells [27].

Statistical Analysis

Comparisons of the proportion of participants demonstrating a response were made using a Pearson chi-square while comparisons on the proportion of participants demonstrating responses across pools were made using a McNemar's Test. Comparisons across study groups were made using a Wilcoxon Rank Sum Tests and comparisons before and after infection were made using paired Wilcoxon Rank Sum Tests. Spearman Rank Correlations were used to assess the correlation between maximum responses post-infection. For each participant, the single highest magnitude of response among the 4 time points was selected for that participant that were defined as greatest number of sfc/10⁶ PBMC at T7, T14 or TLT after the initial SARS-CoV-2 qPCR positive result. All statistical analyses were interpreted using a two-tailed $\alpha=0.05$ and were made using SAS v9.4 or JMP v 12 (SAS Institute; Cary, NC). In some cases, asymptomatic and symptomatic participants who all had responses to the N+M or CD4+CD8 peptide pools

were compared for responses to individual S, N or M peptide pools. In the Supplemental Figures, comparisons of the magnitudes of positive responses after the first qPCR assay were analyzed using the Mann-Whitney U-Test.

RESULTS

Frequency of IFN- γ and IL2 responses to S, N+M, and CD4+CD8 peptide pools before and after infection in the asymptomatic and symptomatic groups

The individual frequencies of IFN- γ and IL2 responses in asymptomatic and symptomatic participants to the S, N+M, and CD4+CD8 pools at T0, T7, T14 and TLT are shown in Supplementary Figures S1 and S2. The frequencies of IFN- γ and IL2 responses to S and N+M pools significantly ($p < 0.001$) rose at 7 days after infection and persisted unchanged at TLT (> 28 days). The exceptions were IFN- γ response to the S protein that significantly declined by TLT among symptomatic but were unchanged among asymptomatic participants, and IL2 responses to the S pool significantly rose at T7 and again at T14 in the asymptomatic group, but not in the symptomatic group. There were no IL2 responses to the CD4+CD8 pool in both groups, except one symptomatic participant who had a positive response.

We next determined the frequency of positive responses at T0, T7, T14 and TLT to the S, N+M and CD4+CD8 peptide pools.

204

205 **S and N+M peptide pools:** among all participants, the frequency of positive IFN- γ responses to
 206 the S pool (30.0%) or the N+M pool (37.0%), was higher among asymptomatic (34.4%, 39.2%,
 207 respectively) than symptomatic (24.8%, 34.3%, respectively) participants; however, only IL2
 208 responses to S pool were significantly higher ($p=0.04$) (Table 1A) in the asymptomatic group.
 209 IFN- γ responses to the N+M pool were significantly more frequent than to the S pool ($p=0.03$),
 210 whereas there was no difference in IL2 responses (Table 1B).

211

212 We next determined whether the frequencies of IFN- γ and IL2 responders to the N+M pool were
 213 associated with the individual N or M pools in asymptomatic and symptomatic participants
 214 (Table 2). Among all participants, IFN- γ responses to the N pool (48.4%) were significantly
 215 ($p=0.002$) higher than to the M pool (21.9%). The frequency of IFN- γ responders to the N pool
 216 (51.4%) was significantly ($p=0.001$) higher than the M pool (18.9%) in asymptomatic
 217 participants ($p=0.001$) but was not significantly different among symptomatic participants
 218 ($p=0.06$). The frequencies of IL2 responses were low compared to IFN- γ responses in each
 219 group.

220

221 **CD4+CD8 peptide pool:** among CD4+CD8 pool responders, the frequency of positive IFN- γ in
 222 matched asymptomatic and symptomatic post-infection to S, N, and M pools were compared.
 223 The responses to the S pool (63.3%) were higher than the N (47.8%) or M (17.4%) pools.
 224 However, in asymptomatic participants IFN- γ responses to S and N pools were similar (55.6%
 225 and 57.1%, respectively) and higher than to the M pool (7.1%) (Table 3), whereas in

symptomatic participants, IFN- γ responses to the S pool were higher (75.0%) than to the N and M pools (33.3% each) (Table 3). This suggests that among asymptomatic participants in this study with IFN- γ responses to the CD4+CD8 pool, responses are generally directed to epitopes within the S pool and N pool and not within the M pool, whereas in symptomatic participants, IFN- γ to the CD4+CD8+ responses are more frequent to epitopes within the S protein than the N protein.

Magnitude of IFN- γ and IL2 responses to S, N+M and CD4+CD8 peptide pools before and after infection in the asymptomatic and symptomatic groups

We next compared the magnitudes of the maximum post-infection responses to each peptide pool in asymptomatic and symptomatic participants. As with determining frequencies of responses, we used the largest magnitude of responses at T0, T7, T14 or TLT.

S and N+M peptide pools: The magnitude of IFN- γ and IL2 responses to the S pool were significantly higher in asymptomatic than symptomatic participants ($p=0.03$ and $p=0.002$, respectively); however, only IL2 responses to the N+M pool were significantly higher in asymptomatic participants ($p=0.04$) (Figure 2). Yet, the magnitude of IFN- γ responses to the N+M pool among all infected participants was higher than the magnitude of responses with S pool (Table 4, $p=0.01$).

Significant correlation (using Spearman Rank Correlations) was observed between maximum post-infection IFN- γ and IL2 responses to the N+M pool and the N pool and the M pool (Figure 3). Maximum IFN- γ responses were more strongly correlated to the N pool (Spearman $R=0.67$, $p<0.0001$) than to the M pool Spearman $R=0.49$, ($p<0.0001$) suggesting the relative importance of responses to the N pool in the responses to the N+M pool.

CD4+CD8 peptide pool: there as a significant correlation (using Spearman Rank Correlations) between the maximum post-infection IFN- γ responses to the CD4+CD8 pool and post-infection IFN- γ responses to the S, N and N+M pools (comparisons excluded the M pool alone group) (Figure 4). These correlations suggest that that responses to the S and N proteins contribute to the CD4+CD8 epitope pool responses, while the contribution of responses to the M pool alone remain undetermined, and we cannot exclude responses to other non-S, N and M proteins in the CD4+CD8 pool. In asymptomatic participants, CD4+CD8 pool responses are generally directed to epitopes within the S protein and N protein and not within the M protein, whereas in symptomatic participants, CD4+CD8+ responses are more frequent to epitopes within the S protein than the N protein (Table 3).

DISCUSSION

This study enabled comparisons of asymptomatic and symptomatic immune responses immediately after a positive SARS-CoV-2 qPCR assay. We used recovered cells from

cryopreserved samples that may not reflect total peripheral T cell counts. Both groups developed frequent and robust IFN- γ responses, although IL2 responses were lower. Others have previously suggested that a significant virus-specific T cell response was not associated with disease severity [7, 28-30], and that total peripheral T cell counts were reduced in asymptomatic patients with reductions in CD4+ and CD8+ T cell counts [31, 32] or greater reductions in CD8 cell counts [31, 33]. Our results suggest that the specificity of responses, notably to the N protein, may be an important indicator of disease status, as symptomatic participants had lower responses to the N protein. We found that asymptomatic participants developed IFN- γ and IL2 responses primarily directed toward the N pool and CD4+CD8 pools, and IFN- γ responses to the N pool were more frequent than to the S pool, whereas symptomatic participants developed responses primarily to the S pool, with lower frequencies of responses to the N, M and CD4+CD8 pools. However, we only assessed asymptomatic and symptomatic participants with mild disease who were all treated as outpatients. Therefore, we cannot extrapolate our findings to other studies using patients with severe disease that suggested lung-homing T cells may contribute to immunopathology, while non-suppressive SARS-CoV-2-specific T cell responses may limit pathogenesis and promote recovery from severe COVID-19 [29].

Early induction of IFN- γ SARS-CoV-2-specific T cell responses to the S protein has been previously associated with mild disease and accelerated viral clearance [28, 30] and the magnitude of responses were more robust in patients with mild disease, whereas those responses were less pronounced in one patient with fatal disease [30]. Using peptide pools in the ELISpot IFN- γ assay, 95% of donors with mild disease had T cell responses to at least one antigen [34]; median aggregate responses were higher in donors with symptomatic disease than asymptomatic

disease, confirming another report using ELISpot IFN- γ [4], and was correlated with peak antibody responses. When CD4+ and CD8+ responses were measured, IL2 responses were dominant in the CD4+ subset. However, there was a greater proportion of CD8+ T cells than CD4+ T cells in mild cases [4]. In convalescent patients, using predicted HLA class I-restricted epitopes, there were distinct patterns of immunodominance for CD4+ and CD8+ T cells, accounting for over 80% of the response, confirming an earlier more limited study [9], and CD4+ and CD8+ responses were highly correlated. Our study extends these findings to include the role of the N protein and CD4+CD8+ T cell responses.

While there are no clearly-defined immune correlates of protection against COVID-19 [35], there is considerable evidence that neutralizing antibodies, an elevated CD8+ T cell response and TH1-biased CD4+ effector responses provide optimal protective immunity [36]. Recent results from convalescent COVID-19 participants indicate that CD4+ and CD8+ T cell responses were similar across different SARS-CoV-2 variants [37]. Thus, it is important to better understand the roles of antibody and T cell responses, including IFN- γ and IL2, after vaccination [38], including in the hybrid immunity of subjects that were infected and then subsequently immunized with a COVID-19 vaccine [39-42], as well as their roles in multisystem inflammatory syndrome in children (MIS-C) and post-acute sequelae SARS-CoV-2 infection (PASC) [43, 44].

A major concern of current antibody-based vaccines are mutations in the S protein that affect sequences recognized by vaccine-induced neutralizing antibodies [45-51]. However, it has been suggested that it is highly unlikely that SARS-CoV-2 mutations would affect T cell immunity as

so many SARS-CoV-2 epitopes are distributed throughout virus [52, 53]. However, mutations in new variants, including the Delta variant, significantly reduced T cell responses to epitope peptides in convalescent and vaccinated subjects [51], and in *in vitro* binding assays [54]. The genetic HLA-restriction of T cell responses associated with disease outcomes would greatly advance our understanding of the relative importance of predicted epitopes including those used in this study, and whether newly emerging variants of concern carry mutations within these protective epitopes. For example, the L452R mutation contributes to evasion of HLA-A24-mediated cellular immunity [55].

Finally, we observed T cell IFN- γ , but not IL2, responses to the S and N+M pool in some uninfected participants, suggesting cross-reactive T cells derived from prior exposure to the common cold human coronaviruses that is in agreement with previous studies that have reported SARS-CoV-2 cross-reactive CD4⁺ T cells in unexposed people [56, 57], and others have speculated whether these may contribute to disease outcomes in COVID-19 [58].

Taken together, our results support previous findings on the potential importance of the N-protein for vaccine development [59]. Immunization with the N protein protects against SARS-CoV-2 in non-human primates [60] and mice [61]. Another advantage to considering the vaccine potential of the N protein is its sequence conservation between SARS-CoV-2 and SARS-CoV and MERS-CoV [62]. The N protein contains a region of T cell cross-reactivity that is common to human alpha and betacoronaviruses, as well as a dominant B cell epitope [63].

Limitations

There are several limitations to this study. Firstly, the study population is young, healthy adults with few comorbidities and may not be reflective of the general population limiting the generalizability of the findings. Secondly, all illnesses were mild, limiting the ability to assess a range of clinical outcomes. Thirdly, the timing of FluoroSpot responses may not have been optimal and further post-infection analyses are warranted. Fourthly, we used cryopreserved cells, and it is possible the recovery of viable cells after thawing may have varied and affected assay readouts. Finally, although we tested immune responses to the S, N and M proteins, it is likely that responses to other proteins may also have a significant role in disease modulation, and responses may partially reflect the relevant sizes of each protein and the numbers of peptides in each pool that were higher for the S pool. We only measured IFN- γ and IL2 producing cells and it is also possible that different cytokines would help to better understand disease severity [30], and phenotypic analysis would also better identify the roles of CD4⁺ and CD8⁺ T cell responses.

ACKNOWLEDGEMENTS

The authors thank Alessandro Sette, Daniela Weiskopf and Alba Grifoni of the Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, who contributed greatly to the success of this project. We also thank Corey Balinsky and Qi Qiu, Naval Medical Research Center, Silver Spring, MD, for their valued technical assistance. MS, CP, EV, and PS are employees of the U.S. Government; CG, DLW, RAL, SEL and AGL are military service members. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government.

Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military Service member or employee of the U.S. Government as part of that person's official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, nor the U.S. Government.

Who Did What:

NAME	Contribution
Martha Sedegah	Conceptualization, Investigation, Supervision, Formal Analysis, Writing rev/edit
Chad Porter	Statistical analysis, formal analysis, visualization, Writing rev/edit
Michael R. Hollingdale	Analysis, Writing Original draft, Writing Rev/Edit
Harini Ganeshan	Investigation, Analysis
Jun Huang	Investigation, Analysis
Carl W. Goforth	Investigation, Project Admin, Funding Acquisition, Resources
Maria Belmonte	Investigation, Analysis
Arnel Belmonte	Investigation, Analysis
Dawn L. Weir	Investigation
Rhonda A. Lizewski	Supervision, Investigation, Project Administration
Stephen E. Lizewski	Supervision, Investigation
Stuart C. Sealfon	Funding Acquisition, Project Coordination, Project Administration
Vihasi Jani	Investigation
Ying Cheng	Investigation
Sandra Inoue	Investigation, Analysis
Rachel Velasco	Investigation, Analysis
Eileen Villasante	Resources, Writing Rev/Edit
Peifang Sun	Conceptualization, Formal Analysis, Writing rev/edit
Andrew Letizia	Conceptualization, Funding, Supervision, Methodology, Resources, Writing Rev/Edit

FUNDING STATEMENT

Supported by a grant (9700130) from the Defense Health Agency through the Naval Medical Research Center and by the Defense Advanced Research Projects Agency (contract number N6600119C4022).

369 REFERENCES

- 370 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with
371 a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3. Epub 2020/02/06. doi:
372 10.1038/s41586-020-2012-7. PubMed PMID: 32015507; PubMed Central PMCID: PMC7095418.
- 373 2. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review
374 and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. *NPJ*
375 *Vaccines*. 2021;6(1):74. Epub 2021/05/15. doi: 10.1038/s41541-021-00336-1. PubMed PMID: 33986272;
376 PubMed Central PMCID: PMC78116645.
- 377 3. Long QX, Jia YJ, Wang X, Deng HJ, Cao XX, Yuan J, et al. Immune memory in convalescent
378 patients with asymptomatic or mild COVID-19. *Cell Discov*. 2021;7(1):18. Epub 2021/03/27. doi:
379 10.1038/s41421-021-00250-9. PubMed PMID: 33767156; PubMed Central PMCID: PMC7993859.
- 380 4. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4(+) and
381 CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol*.
382 2020;21(11):1336-45. Epub 2020/09/06. doi: 10.1038/s41590-020-0782-6. PubMed PMID: 32887977;
383 PubMed Central PMCID: PMC7611020.
- 384 5. Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell and antibody kinetics
385 delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent
386 individuals. *Sci Transl Med*. 2021;13(590). Epub 2021/03/17. doi: 10.1126/scitranslmed.abf7517.
387 PubMed PMID: 33723016; PubMed Central PMCID: PMC78128286.
- 388 6. Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived
389 peptides define heterologous and COVID-19-induced T cell recognition. *Nat Immunol*. 2021;22(1):74-85.
390 Epub 2020/10/02. doi: 10.1038/s41590-020-00808-x. PubMed PMID: 32999467.
- 391 7. Rydzynski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-
392 Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
393 Severity. *Cell*. 2020;183(4):996-1012 e19. Epub 2020/10/05. doi: 10.1016/j.cell.2020.09.038. PubMed
394 PMID: 33010815; PubMed Central PMCID: PMC7494270.
- 395 8. Sohail MS, Ahmed SF, Quadeer AA, McKay MR. In silico T cell epitope identification for SARS-
396 CoV-2: Progress and perspectives. *Adv Drug Deliv Rev*. 2021;171:29-47. Epub 2021/01/20. doi:
397 10.1016/j.addr.2021.01.007. PubMed PMID: 33465451; PubMed Central PMCID: PMC7832442.
- 398 9. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and
399 Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host*
400 *Microbe*. 2020;27(4):671-80 e2. Epub 2020/03/19. doi: 10.1016/j.chom.2020.03.002. PubMed PMID:
401 32183941; PubMed Central PMCID: PMC7142693.
- 402 10. Ranga V, Niemela E, Tamirat MZ, Eriksson JE, Airene TT, Johnson MS. Immunogenic SARS-CoV-2
403 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine
404 Development. *Vaccines (Basel)*. 2020;8(3). Epub 2020/07/29. doi: 10.3390/vaccines8030408. PubMed
405 PMID: 32717854; PubMed Central PMCID: PMC7564651.
- 406 11. Karosiene E, Rasmussen M, Blicher T, Lund O, Buus S, Nielsen M. NetMHCIIpan-3.0, a common
407 pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR,
408 HLA-DP and HLA-DQ. *Immunogenetics*. 2013;65(10):711-24. Epub 2013/08/01. doi: 10.1007/s00251-
409 013-0720-y. PubMed PMID: 23900783; PubMed Central PMCID: PMC3809066.
- 410 12. Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks:
411 application to the MHC class I system. *Bioinformatics*. 2016;32(4):511-7. Epub 2015/10/31. doi:
412 10.1093/bioinformatics/btv639. PubMed PMID: 26515819; PubMed Central PMCID: PMC6402319.

13. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. *J Immunol.* 2017;199(9):3360-8. Epub 2017/10/06. doi: 10.4049/jimmunol.1700893. PubMed PMID: 28978689; PubMed Central PMCID: PMC5679736.
14. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. *Nucleic Acids Res.* 2020;48(W1):W449-W54. Epub 2020/05/15. doi: 10.1093/nar/gkaa379. PubMed PMID: 32406916; PubMed Central PMCID: PMC7319546.
15. Grifoni A, Sidney J, Vita R, Peters B, Crotty S, Weiskopf D, et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. *Cell Host Microbe.* 2021;29(7):1076-92. Epub 2021/07/09. doi: 10.1016/j.chom.2021.05.010. PubMed PMID: 34237248; PubMed Central PMCID: PMC8139264.
16. Lineburg KE, Grant EJ, Swaminathan S, Chatzileontiadou DSM, Szeto C, Sloane H, et al. CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. *Immunity.* 2021;54(5):1055-65 e5. Epub 2021/05/05. doi: 10.1016/j.immuni.2021.04.006. PubMed PMID: 33945786; PubMed Central PMCID: PMC8043652.
17. Szeto C, Chatzileontiadou DSM, Nguyen AT, Sloane H, Lobos CA, Jayasinghe D, et al. The presentation of SARS-CoV-2 peptides by the common HLA-A(*)02:01 molecule. *iScience.* 2021;24(2):102096. Epub 2021/02/02. doi: 10.1016/j.isci.2021.102096. PubMed PMID: 33521593; PubMed Central PMCID: PMC7825995.
18. Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Rep Med.* 2021;2(2):100204. Epub 2021/02/02. doi: 10.1016/j.xcrm.2021.100204. PubMed PMID: 33521695; PubMed Central PMCID: PMC7837622.
19. Schub D, Klemis V, Schneitler S, Mihm J, Lepper PM, Wilkens H, et al. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. *JCI Insight.* 2020;5(20). Epub 2020/09/17. doi: 10.1172/jci.insight.142167. PubMed PMID: 32937615; PubMed Central PMCID: PMC7605520.
20. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. *Med (N Y).* 2021;2(3):281-95 e4. Epub 2021/02/17. doi: 10.1016/j.medj.2021.02.001. PubMed PMID: 33589885; PubMed Central PMCID: PMC7874960.
21. Letizia AG, Ramos I, Obla A, Goforth C, Weir DL, Ge Y, et al. SARS-CoV-2 Transmission among Marine Recruits during Quarantine. *N Engl J Med.* 2020;383(25):2407-16. Epub 2020/11/12. doi: 10.1056/NEJMoa2029717. PubMed PMID: 33176093; PubMed Central PMCID: PMC7675690.
22. Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. *Lancet Respir Med.* 2021;9(7):712-20. Epub 2021/04/19. doi: 10.1016/S2213-2600(21)00158-2. PubMed PMID: 33865504; PubMed Central PMCID: PMC8049591 of the study. DS and FK have filed a patent regarding serological assays for SARS-CoV-2 and Icahn School of Medicine at Mount Sinai has founded a company to commercialise serological assays they developed. AGL, CG, DLW, HWC, DE, WDG, FJ, JM, EN, CKP, ESA, MS, VAS, RAL, SEL, PS, MT, and PS are military service members or government service employees. This work was prepared as part of their official duties. Title 17, US Code section sign105 provides that copyright protection under this title is not available for any work of the US Government. Title 17, US code section sign101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties. The views expressed in the article are those of the authors and do not necessarily express the official policy and position of the US Navy, the Department of Defense, the US Government or the institutions affiliated with the authors.

- AGL, YG, SV, CG, DLW, HWC, NAK, CAB, DE, M-CG, WDG, FJ, RAL, SEL, JM, NM, CMM, PB, SM, VDN, EN, CKP, ESA, AS-S, MS, VAS, MT, PS, RPT, AB, IR, and SCS declare no competing interests.
23. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, et al. Adenovirus 5-vectored *P. falciparum* vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. *PLoS One*. 2011;6(10):e24586. Epub 2011/10/18. doi: 10.1371/journal.pone.0024586. PubMed PMID: 22003383; PubMed Central PMCID: PMC3189181.
24. Hickey B, Teneza-Mora N, Lumsden J, Reyes S, Sedegah M, Garver L, et al. IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated *P. falciparum* sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents. *PLoS One*. 2020;15(6):e0233840. Epub 2020/06/20. doi: 10.1371/journal.pone.0233840. PubMed PMID: 32555601.
25. Hickey BW, Lumsden JM, Reyes S, Sedegah M, Hollingdale MR, Freilich DA, et al. Mosquito bite immunization with radiation-attenuated *Plasmodium falciparum* sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. *Malar J*. 2016;15(1):377. doi: 10.1186/s12936-016-1435-y. PubMed PMID: 27448805; PubMed Central PMCID: PMC4957371.
26. Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, et al. Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes. *PLoS One*. 2014;9(9):e106241. doi: 10.1371/journal.pone.0106241. PubMed PMID: 25211344.
27. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/Adenovirus boost malaria vaccine encoding *P. falciparum* CSP and AMA1 induces sterile protection associated with cell-mediated immunity. *PLoS One*. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. PubMed PMID: 23457473; PubMed Central PMCID: PMC3573028.
28. Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med*. 2021;218(5). Epub 2021/03/02. doi: 10.1084/jem.20202617. PubMed PMID: 33646265; PubMed Central PMCID: PMC7927662 SARS-CoV-2-specific T cells in biological samples pending. W.N. Chia reported a patent for a sublicense agreement with GenScript for the surrogate virus neutralization test pending (Duke-NUS). P. Tambyah reported grants from Arcturus, Roche, Shionogi, Sanofi-Pasteur, and Aj Biologics outside the submitted work. L. Wang reported a patent application on sVNT pending. A. Bertoletti reported personal fees from Oxford Immunotech and Qiagen outside the submitted work; in addition, A. Bertoletti had a patent for the use of peptide pools in whole blood for detection of SARS-CoV-2 T cells pending. C.C. Tam reported grants from Roche and personal fees from Verivax outside the submitted work. No other disclosures were reported.
29. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. *Cell Rep*. 2021;36(3):109414. Epub 2021/07/15. doi: 10.1016/j.celrep.2021.109414. PubMed PMID: 34260965; PubMed Central PMCID: PMC8238659.
30. Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep*. 2021;34(6):108728. Epub 2021/02/01. doi: 10.1016/j.celrep.2021.108728. PubMed PMID: 33516277; PubMed Central PMCID: PMC7826084.
31. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *J Clin Invest*. 2020;130(9):4694-703. Epub 2020/05/29. doi: 10.1172/JCI138554. PubMed PMID: 32463803; PubMed Central PMCID: PMC7456250.
32. Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. *J Infect*. 2020;81(1):e51-e60.

- Epub 2020/04/22. doi: 10.1016/j.jinf.2020.04.012. PubMed PMID: 32315725; PubMed Central PMCID: PMCPMC7166040.
33. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2021;16(1):e0245532. Epub 2021/01/26. doi: 10.1371/journal.pone.0245532. PubMed PMID: 33493185; PubMed Central PMCID: PMCPMC7833159 organisation for the submitted work; JM is chief scientific officer, shareholder and scientific founder of Leucid Bio, a spinout company focused on development of cellular therapeutic agents; no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
34. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021;22(5):620-6. Epub 2021/03/07. doi: 10.1038/s41590-021-00902-8. PubMed PMID: 33674800; PubMed Central PMCID: PMCPMC7610739.
35. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52(6):910-41. Epub 2020/06/09. doi: 10.1016/j.immuni.2020.05.002. PubMed PMID: 32505227; PubMed Central PMCID: PMCPMC7200337 Checkpoint Sciences, Primevax, Novartis, Array BioPharma, Roche, Avidex, Boehringer Ingelheim, Rome Therapeutics, Roswell Park, and the Parker Institute for Cancer Immunotherapy. N.B. receives research support from the Parker Institute, Novocure, Celldex, Genentech, Oncovir, and Regeneron. M.M. serves as an advisor/board member for Celsius, Pionyr, Compugen, Myeloids and Innate pharma and ad hoc for Takeda. M.M. receives research support from Regeneron, Takeda, and Genentech. A.M. has equity in Gilead Sciences and Regeneron Pharmaceuticals.
36. Jeyanathan M, Afkhami S, Smail F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-32. Epub 2020/09/06. doi: 10.1038/s41577-020-00434-6. PubMed PMID: 32887954; PubMed Central PMCID: PMCPMC7472682.
37. Tarke A, Sidney J, Methot N, Zhang Y, Dan JM, Goodwin B, et al. Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv. 2021. Epub 2021/03/11. doi: 10.1101/2021.02.27.433180. PubMed PMID: 33688655; PubMed Central PMCID: PMCPMC7941626.
38. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93. Epub 2020/08/14. doi: 10.1038/s41586-020-2639-4. PubMed PMID: 32785213.
39. Crotty S. Hybrid Immunity. Science. 2021;372(6549):1392-3. doi: DOI: 10.1126/science.abj2258.
40. Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M, et al. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. 2021;68:103401. Epub 2021/05/30. doi: 10.1016/j.ebiom.2021.103401. PubMed PMID: 34051441; PubMed Central PMCID: PMCPMC8149267 Sedaghat Herati, and Mohammad M. Sajadi have nothing to disclose. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 95 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor (US Provisional Application No 62/994,252). Viviana Simon is also listed on the serological assay patent application as co-inventor (US Provisional Application No 62/994,252). Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. Alberto Mantovani has consulted for Pfizer and Astra Zeneca. Maria Rescigno serves as a consultant for DiaSorin and Gelesis. Diasorin supports Humanitas for the development of diagnostic assays related to COVID-19 and has filed patent applications with Alberto Mantovani as co-inventor.

41. Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*. 2021. Epub 2021/03/27. doi: 10.1126/science.abg9175. PubMed PMID: 33766944; PubMed Central PMCID: PMC8139425.
 42. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science*. 2021. Epub 2021/05/02. doi: 10.1126/science.abh1282. PubMed PMID: 33931567; PubMed Central PMCID: PMC8168614.
 43. Goletti D, Petrone L, Manissero D, Bertoletti A, Rao S, Ndunda N, et al. The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. *Clin Microbiol Infect*. 2021. Epub 2021/07/14. doi: 10.1016/j.cmi.2021.07.005. PubMed PMID: 34256141; PubMed Central PMCID: PMC8272618.
 44. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nat Med*. 2021;27(2):270-8. Epub 2020/12/19. doi: 10.1038/s41591-020-01194-5. PubMed PMID: 33335323.
 45. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. *Nature*. 2021;593(7857):142-6. Epub 2021/03/30. doi: 10.1038/s41586-021-03471-w. PubMed PMID: 33780970.
 46. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat Med*. 2021;27(4):717-26. Epub 2021/03/06. doi: 10.1038/s41591-021-01294-w. PubMed PMID: 33664494; PubMed Central PMCID: PMC8058618.
 47. Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature*. 2021;593(7857):136-41. Epub 2021/03/12. doi: 10.1038/s41586-021-03412-7. PubMed PMID: 33706364.
 48. Hoffmann M, Hofmann-Winkler H, Kruger N, Kempf A, Nehlmeier I, Graichen L, et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. *Cell Rep*. 2021;36(3):109415. Epub 2021/07/17. doi: 10.1016/j.celrep.2021.109415. PubMed PMID: 34270919; PubMed Central PMCID: PMC8238662.
 49. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell*. 2021;184(9):2384-93 e12. Epub 2021/04/02. doi: 10.1016/j.cell.2021.03.036. PubMed PMID: 33794143; PubMed Central PMCID: PMC80144.
 50. Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O'Toole A, et al. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. *Cell*. 2021;184(1):64-75 e11. Epub 2020/12/05. doi: 10.1016/j.cell.2020.11.020. PubMed PMID: 33275900; PubMed Central PMCID: PMC7674007.
 51. Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8(+) T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. *Cell Rep*. 2021;36(11):109708. Epub 2021/09/11. doi: 10.1016/j.celrep.2021.109708. PubMed PMID: 34506741; PubMed Central PMCID: PMC8390359.
 52. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*. 2020;181(7):1489-501 e15. Epub 2020/05/31. doi: 10.1016/j.cell.2020.05.015. PubMed PMID: 32473127; PubMed Central PMCID: PMC7237901.
 53. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 2021;184(4):861-80. Epub 2021/01/27. doi: 10.1016/j.cell.2021.01.007. PubMed PMID: 33497610; PubMed Central PMCID: PMC7803150
- Epitogenesis, Gilead, and Aivalia. S.C. is a consultant for Aivalia. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.

54. Agerer B, Koblishke M, Gudipati V, Montano-Gutierrez LF, Smyth M, Popa A, et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses. *Sci Immunol.* 2021;6(57). Epub 2021/03/06. doi: 10.1126/sciimmunol.abg6461. PubMed PMID: 33664060; PubMed Central PMCID: PMC8224398.
55. Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. *Cell Host Microbe.* 2021;29(7):1124-36 e11. Epub 2021/06/26. doi: 10.1016/j.chom.2021.06.006. PubMed PMID: 34171266; PubMed Central PMCID: PMC8205251.
56. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science.* 2020;370(6512):89-94. Epub 2020/08/06. doi: 10.1126/science.abd3871. PubMed PMID: 32753554; PubMed Central PMCID: PMC7574914.
57. Capoor MN, Ahmed FS, McDowell A, Slaby O. Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2? *Front Cell Infect Microbiol.* 2020;10:605334. Epub 2021/01/05. doi: 10.3389/fcimb.2020.605334. PubMed PMID: 33392109; PubMed Central PMCID: PMC7775357.
58. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nat Rev Immunol.* 2020;20(8):457-8. Epub 2020/07/09. doi: 10.1038/s41577-020-0389-z. PubMed PMID: 32636479; PubMed Central PMCID: PMC7339790.
59. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. *J Virol.* 2020;94(13). Epub 2020/06/18. doi: 10.1128/JVI.00647-20. PubMed PMID: 32546606; PubMed Central PMCID: PMC7307180.
60. Hong SH, Oh H, Park YW, Kwak HW, Oh EY, Park HJ, et al. Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates. *Sci Adv.* 2021;7(22). Epub 2021/05/30. doi: 10.1126/sciadv.abg7156. PubMed PMID: 34049881.
61. Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, et al. Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. *J Immunol.* 2021. Epub 2021/07/02. doi: 10.4049/jimmunol.2100421. PubMed PMID: 34193597.
62. Ong E, Huang X, Pearce R, Zhang Y, He Y. Rational Design of SARS-CoV-2 Spike Glycoproteins To Increase Immunogenicity By T Cell Epitope Engineering. *bioRxiv.* 2020. Epub 2020/08/21. doi: 10.1101/2020.08.14.251496. PubMed PMID: 32817949; PubMed Central PMCID: PMC7430581.
63. Oliveira SC, de Magalhaes MTQ, Homan EJ. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. *Front Immunol.* 2020;11:587615. Epub 2020/11/17. doi: 10.3389/fimmu.2020.587615. PubMed PMID: 33193414; PubMed Central PMCID: PMC7655779.

Table 1. Frequency of immune responses to the S and N+M peptide pools in asymptomatic and symptomatic participants

A					
IFN- γ	Asymptomatic (n=124)	Symptomatic (n=105)	All participants (n=229)	P-value	
S Pool	43 (34.7%)	26 (24.8%)	69 (30.1%)	0.10	
N+M pool	49 (39.5%)	36 (34.3%)	85 (37.1%)	0.41	
IL2					
S Pool	19 (15.3%)	7 (6.7%)	26 (11.4)	0.04	
N+M pool	13 (10.5%)	10 (9.5%)	23 (10.0)	0.81	
B					
IFN- γ		N+M pool		Total	P-value
		Responder	Non-Responder		
S pool	Responder	51	18	69	
	Non-Responder	34	126	160	
Total		85	144	229	0.03
IL2		N+M pool			0.5
		Responder	Non-Responder		
S pool	Responder	12	14	26	
	Non-Responder	11	192	203	
Total		23	206	229	

Panel A: comparison of the numbers and percent of asymptomatic and symptomatic participants with positive IFN- γ or IL2 responses post-infection to the S pool or the N+M pool. The frequency of IFN- γ responses to the S and N+M pool were higher in asymptomatic than symptomatic participants, although the differences were not statistically different between asymptomatic and symptomatic participants. However, the frequency of IL2 responses to the S pool was significantly higher among asymptomatic than symptomatic participants ($p=0.04$). The frequency of IL2 responses to the N+M pool were higher in asymptomatic than in symptomatic participants, although the difference was not statistically different.

Panel B: the numbers of IFN- γ or IL2 responses of all participants (asymptomatic and symptomatic) to the S and N+M peptide pools were compared using McNemar's Chi-Square. IFN- γ responses to the N+M pool among all infected participants were more frequent (37.1%) than IFN- γ responses to the S pool (30.1%) ($p=0.03$), but not IL2 responses ($p=0.5$).

Comparison of the frequencies and magnitudes of responses are shown in Figure S1 and Figure S2.

Table 2. Frequency of immune responses to the N+M, N, and M peptide pools in post-infection asymptomatic and symptomatic participants

Cytokine	Pool	Asymptomatic N+M pool responders	Symptomatic N+M pool responders	All participants N+M pool responders
IFN-γ	N pool	19/37 (51.4%)	12/27 (44.4%)	31/64 (48.4%)
	M pool	7/37 (18.9%)	7/27 (25.9%)	14/64 (21.9%)
	p-value	0.001	0.06	0.002
IL-2	N pool	2/9 (22.2%)	0/8 (0%)	2/17 (11.8%)
	M pool	2/9 (22.2%)	1/8 (12.5%)	3/17 (17.7%)
	p-value	1.0	--	0.6

The numbers and percent positive of asymptomatic and symptomatic participants with positive IFN- γ or IL2 responses post-infection to the N+M pool were compared with responses to the individual N or M pools.

Table 3. Frequency IFN- γ and IL2 responses to CD4+CD8 pools and S, N, and M pools in matched asymptomatic and symptomatic post-infection participants

Cytokine	Pool	Asymptomatic CD4+CD8 pool responders	Symptomatic CD4+CD8 pool responders	All participants CD4+CD8 pool responders
IFN- γ	S pool	10/18 (55.6%)	9/12 (75.0%)	19/30 (63.3%)
	N pool	8/14 (57.1%)	3/9 (33.3%)	11/23 (47.8%)
	M pool	1/14 (7.1%)	3/9 (33.3%)	4/23 (17.4%)
IL-2	S pool	Low	Low	Low
	N pool	Low	Low	Low
	M pool	Low	Low	Low

The numbers and percent positive of asymptomatic and symptomatic participants with positive IFN- γ or IL2 responses post-infection to the CD4+CD8 pool were compared in matched participants with responses to the individual S, N, or M pools. Low responders had activities that did not meet the positivity criteria (Methods).

Table 4. Magnitude of IFN- γ and IL2 responses to the S and N+M peptide pools among all infected participants (N=229)

IFN-γ	Mean (Std. Dev.)	Median (Q1, Q3)	P value*
S pool	40.4 (43.4)	30.0 (13.3, 52.5)	0.01
N+M pool	46.7 (50.7)	32.5 (15.0, 67.5)	
IL2			
S pool	19.3 (26.5)	12.5 (3.8, 27.5)	0.2
N+M pool	17.7 (23.4)	10.0 (3.8, 22.5)	

Responses were expressed as box plots: Std. Dev.: standard deviation; Q1: Quartile 1; Q3: quartile 3; *Signed Rank Test.

Table S1: Distribution of predicted CD4+ and CD8+ epitopes within SARS-CoV-2 proteins

	Number of peptides predicted within protein						Total
T cell type	S protein	N protein	M protein	E protein	NS protein	Other Proteins	
Number CD4 Epitopes/protein	20	7	8	8	101	97	241
% CD4 Epitopes/Total	8.30	2.90	3.32	3.32	41.91	40.25	
Number CD8 Epitopes/protein	86	13	15	2	227	285	628
% CD8 Epitopes/Total	13.69	2.07	2.39	0.32	36.15	45.38	

CD4+ and CD8+ epitopes within each SARS-CoV-2 protein were predicted [52], synthesized, and combined in the CD4+CD8 peptide pool.

Figure 1. Participant Flow: times of FluoroSpot assays relative to the first positive PCR test

Participants were enrolled in the initial prospective study and tested by qPCR biweekly initially and then bimonthly. When qPCR positive, the participant was transferred to the immune response subgroup within 48-96 hours (7d*) and tested by qPCR biweekly and bimonthly thereafter. PBMCs were isolated (red arrows) prior to the initial qPCR (at enrollment, T0), and once positive at 3/4 days 7 days (grouped into T7), 10/11 days (grouped into T14), and greater than 28 days (time long-term (grouped into TLT) post qPCR positivity for SARS-CoV-2.

Figure 2. Magnitudes of IFN- γ and IL2 responses of asymptomatic, symptomatic participants before and after infection, and healthy uninfected participants, to S, N+M, and CD4+CD8 pools

Pre-infection (Pre) and maximum IFN- γ and IL2 responses post-infection (Post) to S, N+M, and CD4+CD8 peptide pools of asymptomatic and symptomatic participants, and healthy uninfected participants (Pre = baseline and Post = post-baseline). Significance of differences between Pre and Post *** $p < 0.001$.

Figure 3. Correlations of the magnitude of IFN- γ and IL2 responses post-infection to the N and M pools with IFN- γ and IL2 responses to the N+M pool

The maximum IFN- γ and IL2 responses post-infection to the N and M pools were compared to those to the mixture of N+M pool in matched participants by Spearman Rank Correlations.

Figure 4. Correlations of the magnitude of IFN- γ responses post-infection to the S, N, and N+M pools with IFN- γ responses to the CD4+CD8 pool

The magnitudes of IFN- γ responses to the CD4+CD8 pool were compared to the magnitudes of IFN- γ responses to the S, N, and N+M pools. Using Spearman's ranked correlations, IFN- γ responses to the S, N and N+M pools were significantly correlated.

Figure S1: Asymptomatic participants: magnitude and percent positivity of IFN- γ and IL2 responses to the S, N+M and CD4+CD8 peptide pools

*** $p < 0.001$; * $p < 0.05$

The numbers of samples at each time point were based on the numbers of available samples among the 124 asymptomatic participants. Immune responses (sfc/m) and percent positive participants are shown before the first positive qPCR test (T0), 7 days (T7), 14 days (T14) and long-term (TLT) after that first positive PCR test (infection). Immune responses to S, N+M and CD4+CD8 pools were significantly ($p < 0.001$) higher at T7, and were not significantly different between T7, T14 and TLT after infection; the exception was the significant rise in IL2 responses to S pool between 7d and 14d after infection. There were no positive IL2 responses to the CD4+CD8 pool.

Figure S2: Symptomatic participants: magnitude and percent positivity of IFN- γ and IL2 responses to the S, N+M and CD4+CD8 peptide pools

*** $p < 0.001$; ** $p < 0.01$

The numbers of samples at each time point were based on the numbers of available samples among the 105 symptomatic participants. Immune responses (sfc/m) and percent positive participants are shown before the first positive PCR test (T0), and 7 days (T7), 14 days (T14) and long-term (TLT) after that first positive PCR test (infection). Immune responses to S, N+M and CD4+CD8 pools were significantly ($p < 0.001$) higher at T7, and IFN- γ responses to S protein significantly dropped by TLT. IL2 responses to the CD4+CD8 pool were absent, except in one participant at 14d after infection.

Initial Prospective Study

All Participants

Immune Response Subgroup

qPCR+ve Participants

Figure 1

Figure 2

Figure 3

Figure 4